![]() | |
Clinical data | |
---|---|
Trade names | Manyper, Caldine, etc. |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C35H38N4O6 |
Molar mass | 610.711 g·mol−1 |
3D model (JSmol) | |
| |
|
Manidipine is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive.[1][2][3][4][5]
It was patented in 1982 and approved for medical use in 1990.[6]
Synthesis
[edit]![](https://upload.wikimedia.org/wikipedia/commons/thumb/6/6f/Manidipine_synthesis.svg/500px-Manidipine_synthesis.svg.png)
The alkylation between N-(2-hydroxyethyl)piperazine [103-76-4] (1) and Benzhydryl Bromide [776-74-9] (2) gives 2-(4-benzhydrylpiperazin-1-yl)ethanol [10527-64-7] (3). The reaction with Diketene [674-82-8] (4) gives 2-(4-benzhydryl-1-piperazinyl)ethyl acetoacetate [89226-49-3] (5). The reaction with 3-nitrobenzaldehyde [99-61-6] (6) and Methyl 3-aminocrotonate [14205-39-1] (7) completed the synthesis of Manidipine (8).
References
[edit]- ^ Cheer SM, McClellan K (2001). "Manidipine: a review of its use in hypertension". Drugs. 61 (12): 1777–1799. doi:10.2165/00003495-200161120-00010. PMID 11693466. S2CID 260814599. Archived from the original on 2013-01-17. Retrieved 2009-06-20.
- ^ McKeage K, Scott LJ (2004). "Manidipine: a review of its use in the management of hypertension". Drugs. 64 (17): 1923–1940. doi:10.2165/00003495-200464170-00011. PMID 15329044. S2CID 195689527. Archived from the original on 2013-01-16. Retrieved 2009-06-20.
- ^ Roca-Cusachs A, Triposkiadis F (2005). "Antihypertensive effect of manidipine". Drugs. 65 (Suppl 2): 11–19. doi:10.2165/00003495-200565002-00003. PMID 16398058. S2CID 25854593. Archived from the original on 2013-01-16. Retrieved 2009-06-20.
- ^ Otero ML (2007). "Manidipine-delapril combination in the management of hypertension". Vascular Health and Risk Management. 3 (3): 255–263. PMC 2293964. PMID 17703633.
- ^ Mizuno K, Haga H, Takahashi M, Fukuchi S (August 1992). "Evaluation of manidipine hydrochloride, a new calcium antagonist, in the treatment of hypertensive patients with renal disorders". Current Therapeutic Research. 52 (2): 248–253. doi:10.1016/S0011-393X(05)80475-8.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 465. ISBN 9783527607495.
- ^ Meguro, Kanji; Aizawa, Masahiro; Sohda, Takashi; Kawamatsu, Yutaka; Nagaoka, Akinobu (1985). "New 1,4-dihydropyridine derivatives with potent and long-lasting hypotensive effect.". CHEMICAL & PHARMACEUTICAL BULLETIN. 33 (9): 3787–3797. ISSN 0009-2363. doi:10.1248/cpb.33.3787.
- ^ EP0094159 idem Kanji Meguro & Akinobu Nagaoka, US4892875 (1990 to Takeda Pharmaceutical Co Ltd).
- ^ Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Maruti Ganpati Ghagare, WO20110203954 (2011 to Cipla Limited, Curtis, Philip Anthony).
- ^ 刘玉海, et al. CN105924382 (2018).
- ^ 金晓峰, et al. CN102875451 (2014 to CHANGZHOU PHARMACEUTICAL FACTORY CO LTD).
- ^ 刘忠春, CN107337632 (2017).
- ^ 谷志勇, et al. CN104292150 (2015).
- ^ , CN103351362 (2013 to).
- ^ http://en.cnki.com.cn/Article_en/CJFDTOTAL-ZHOU200402000.htm